Inhibitor Report for: Cyclic-Hydrazine-Derivative General
Type Trifluoro , Diazepan , Azepane Chemical_Nomenclature (3R)-3-amino-1-(2-benzoyldiazepan-1-yl)-4-(2,4,5-trifluorophenyl)butan-1-one Canonical SMILES C1CCN(N(CC1)C(=O)C2=CC=CC=C2)C(=O)CC(CC3=CC(=C(C=C3F)F)F)N InChI InChI=1S/C22H24F3N3O2/c23-18-14-20(25)19(24)12-16(18)11-17(26)13-21(29)27-9-5-2-6-10-28(27)22(30)15-7-3-1-4-8-15/h1,3-4,7-8,12,14,17H,2,5-6,9-11,13,26H2/t17-/m1/s1 InChIKey XXRHRPGYYNOBHO-QGZVFWFLSA-N Other name(s) KR2 ; CHEMBL513425 ; (2r)-4-(2-Benzoyl-1,2-Diazepan-1-Yl)-4-Oxo-1-(2,4,5-Trifluorophenyl)butan-2-Amine ; CHEMBL539611 ; BDBM50206820 ; BDBM50256266 ; DB08051
________________________________________________________________________________________________
Target
Families | Cyclic-Hydrazine-Derivative ligand of proteins in family: DPP4N_Peptidase_S9 Stucture | 1 structure : 2OLE : Crystal Structure Of Human Dipeptidyl Peptidase IV (DPPIV) Complex With Cyclic Hydrazine Derivatives Protein | human-DPP4
References:
Title: Synthesis, biological evaluation and structural determination of beta-aminoacyl-containing cyclic hydrazine derivatives as dipeptidyl peptidase IV (DPP-IV) inhibitorsAhn JH , Shin MS , Jun MA , Jung SH , Kang SK , Kim KR , Rhee SD , Kang NS , Kim SY and Kim SS <5 more author(s)> Ahn JH , Shin MS , Jun MA , Jung SH , Kang SK , Kim KR , Rhee SD , Kang NS , Kim SY , Sohn SK , Kim SG , Jin MS , Lee JO , Cheon HG , Kim SS (- 5) Ref: Bioorganic & Medicinal Chemistry Lett, 17 :2622, 2007 : PubMed Abstract ESTHER: Ahn_2007_Bioorg.Med.Chem.Lett_17_2622 PubMedSearch: Ahn 2007 Bioorg.Med.Chem.Lett 17 2622 PubMedID: 17331715 Gene_locus related to this paper: human-DPP4 Inhibitor(s) related to this paper: Cyclic-Hydrazine-Derivative Abstract
Inhibitors of dipeptidyl peptidase IV (DPP-IV) have been shown to be effective treatments for type 2 diabetes. A series of beta-aminoacyl-containing cyclic hydrazine derivatives were synthesized and evaluated as DPP-IV inhibitors. One member of this series, (R)-3-amino-1-(2-benzoyl-1,2-diazepan-1-yl)-4-(2,4,5-trifluorophenyl)butan-1-one (10f), showed potent in vitro activity, good selectivity and in vivo efficacy in mouse models. Also, the binding mode of compound 10f was determined by X-ray crystallography.
